Health Condition 1: null- All females of age â?º 20-65 years, diagnosed with epilepsy. Patients receiving sodium valproate, carbamazepine or levetiracetam as monotherapy for atleast a year.
Conditions
Interventions
None listed
Sponsors
Department of Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: Patients receiving sodium valproate, carbamazepine or levetiracetam as monotherapy for atleast a year.
Exclusion criteria
Exclusion criteria: Women with conditions known to affect bone and mineral metabolism (such as primary hyperparathyroidism, Pagetâ??s disease, multiple myeloma, hepatic or renal disorders, diabetes mellitus, thyroid diseases, malignancy or malabsorption) Women taking glucocorticoids that are known to affect bone and mineral metabolism. Patients in which sodium valproate, carbamazepine and levetiracetam are prescribed for condition other than epilepsy. Patients with smoking habit. Patients who refuse to give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the serum levels of bone turnover markers in women on AEDs and healthy women: Sclerostin, DKK1, RANKL and Vitamin D.Timepoint: Sample is taken once between 9 am to 1 pm. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of age, duration and dose of AEDs on biomarkers.Timepoint: Sample is taken once between 9 am to 1pm. | — |
Countries
India
Contacts
Public ContactDivya Vohora
Jamia Hamdard
Outcome results
None listed